Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

NCT05669599

Amgen · Phase 2 · Completed · Enrollment 592

NCT05669599

ArmPopulationDoseWeeksEstimandWeight change
Cohort A: Maridebart CafraglutideObesity or overweightn/r52ITTn/r
Cohort A: PlaceboPopulation n/rn/rn/rn/rn/r
Cohort B: Maridebart CafraglutidePopulation n/rn/rn/rn/rn/r
Cohort B: PlaceboPopulation n/rn/rn/rn/rn/r